{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wilson RL"],"funding":["Eunice Kennedy Shriver National Institute of Child Health and Human Development","NICHD NIH HHS"],"pagination":["540-553"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10947605"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["89(11)"],"pubmed_abstract":["Fetal growth restriction (FGR) significantly contributes to neonatal and perinatal morbidity and mortality. Currently, there are no effective treatment options for FGR during pregnancy. We have developed a nanoparticle gene therapy targeting the placenta to increase expression of human insulin-like growth factor 1 (hIGF1) to correct fetal growth trajectories. Using the maternal nutrient restriction guinea pig model of FGR, an ultrasound-guided, intraplacental injection of nonviral, polymer-based hIGF1 nanoparticle containing plasmid with the hIGF1 gene and placenta-specific Cyp19a1 promotor was administered at mid-pregnancy. Sustained hIGF1 expression was confirmed in the placenta 5 days after treatment. Whilst increased hIGF1 did not change fetal weight, circulating fetal glucose concentr"],"journal":["Molecular reproduction and development"],"pubmed_title":["Nanoparticle-mediated transgene expression of insulin-like growth factor 1 in the growth restricted guinea pig placenta increases placenta nutrient transporter expression and fetal glucose concentrations."],"pmcid":["PMC10947605"],"funding_grant_id":["R01 HD090657"],"pubmed_authors":["Duvall CL","Gupta MK","Wilson RL","Lampe K","Jones HN"],"additional_accession":[]},"is_claimable":false,"name":"Nanoparticle-mediated transgene expression of insulin-like growth factor 1 in the growth restricted guinea pig placenta increases placenta nutrient transporter expression and fetal glucose concentrations.","description":"Fetal growth restriction (FGR) significantly contributes to neonatal and perinatal morbidity and mortality. Currently, there are no effective treatment options for FGR during pregnancy. We have developed a nanoparticle gene therapy targeting the placenta to increase expression of human insulin-like growth factor 1 (hIGF1) to correct fetal growth trajectories. Using the maternal nutrient restriction guinea pig model of FGR, an ultrasound-guided, intraplacental injection of nonviral, polymer-based hIGF1 nanoparticle containing plasmid with the hIGF1 gene and placenta-specific Cyp19a1 promotor was administered at mid-pregnancy. Sustained hIGF1 expression was confirmed in the placenta 5 days after treatment. Whilst increased hIGF1 did not change fetal weight, circulating fetal glucose concentr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T12:09:36.396Z","creation":"2025-02-19T03:08:23.18Z"},"accession":"S-EPMC10947605","cross_references":{"pubmed":["36094907"],"doi":["10.1002/mrd.23644"]}}